What is Oricell Therapeutics's official website?

Oricell Therapeutics's website is https://www.oricell.com/en/

How many employees are working in Oricell Therapeutics right now?

Oricell Therapeutics has 24 employees.

What is Oricell Therapeutics's industry?

Oricell Therapeutics's industry is Biotechnology

Who are Oricell Therapeutics's top competitors?

Oricell Therapeutics's top competitors are , , , , , ,

Oricell Therapeutics company information, Employees & Contact Information

Explore related pages

Oricell Therapeutics email format Oricell Therapeutics management contacts

Related company profiles:

Founded in 2015, Oricell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.

Employees: 24
Address: 1227 Zhangheng Rd, Third Floor,building #1,china
Industry: Biotechnology
Website: https://www.oricell.com/en/
Keywords: Manager jobs.
HQ: Shanghai
Competitors: Artiva Biotherapeutics, Acepodia, Shanghai Allist Pharmaceuticals Co., Ltd, Elicio Therapeutics, REGENXBIO, Beam Therapeutics, Strand Therapeutics, GenScript, CARsgen Therapeutics, Poseida Therapeutics, Inc..

Oricell Therapeutics Questions

News

Ori's cell and gene platform wins key FDA advanced manufacturing designation - Fierce Pharma

Ori's cell and gene platform wins key FDA advanced manufacturing designation Fierce Pharma

The first clinical-stage dual-payload conjugate | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

The first clinical-stage dual-payload conjugate | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias - Frontiers

Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias Frontiers

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma. - PR Newswire

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma. PR Newswire

Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO Annual Meeting, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy - BioSpace

Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO Annual Meeting, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy BioSpace

ORIC-613 is dual-target CAR T-cell therapy - BioWorld MedTech

ORIC-613 is dual-target CAR T-cell therapy BioWorld MedTech

JPM24: Flagship chief says firm will have to ‘do some work’ before linking with China-based partners - Fierce Biotech

JPM24: Flagship chief says firm will have to ‘do some work’ before linking with China-based partners Fierce Biotech

RTW funds Oricell Therapeutics - QuotedData

RTW funds Oricell Therapeutics QuotedData

Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission - Fierce Biotech

Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission Fierce Biotech

Companies like Oricell Therapeutics

Top Oricell Therapeutics Employees

Hiren Italiya

Manufacturing Science And Analytical Technology (Msat) / Analytical Development /Qc Expert (Car-T, Nk, Γδ T, Stem Cell, T-Reg)

N/a

View
Bruce Ng

Gene/Cell Therapy Cmc Program Management

Princeton, New Jersey, United States, United States

View

3
graphitebio.com, yahoo.com, wuxiapptec.com
Hong Ma

Senior Md In Cancer Immunotherapy & Autoimmune Diseases

Houston, Texas, United States, United States

View

2
yahoo.com, carsgen.com
Xu (Dawn) Guo

Bd Head

China, China

View

1
gmail.com

1 +171857XXXXX

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles

Get direct phone numbers & mobile contacts

Access company data & employee information

Works directly on LinkedIn - no copy/paste needed

Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Learn More

How It Works

Get a Free Account

Search the #1 Contact Database

Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.

Use our AI-Powered Email Finder

Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.

Have a look at Aeroleads Data

Browse our Data

Company Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Profile Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

List Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Oricell Therapeutics company information, Employees & Contact Information

Explore related pages

Company Details

Oricell Therapeutics Questions

What is Oricell Therapeutics's official website?

What is Oricell Therapeutics's LinkedIn profile?

How many employees are working in Oricell Therapeutics right now?

What is Oricell Therapeutics's industry?

What are Oricell Therapeutics's top competitors?

What are Oricell Therapeutics's categories?

News

Ori's cell and gene platform wins key FDA advanced manufacturing designation - Fierce Pharma

The first clinical-stage dual-payload conjugate | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias - Frontiers

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma. - PR Newswire

Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO Annual Meeting, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy - BioSpace

ORIC-613 is dual-target CAR T-cell therapy - BioWorld MedTech

JPM24: Flagship chief says firm will have to ‘do some work’ before linking with China-based partners - Fierce Biotech

RTW funds Oricell Therapeutics - QuotedData

Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission - Fierce Biotech

Companies like Oricell Therapeutics

Genscript

Elicio Therapeutics

Strand Therapeutics

Artiva Biotherapeutics

Shanghai Allist Phar...

Poseida Therapeutics...

Carsgen Therapeutics

Beam Therapeutics

Acepodia

Regenxbio

Top Oricell Therapeutics Employees

Hiren Italiya

Manufacturing Science And Analytical Technology (Msat) / Analytical Development /Qc Expert (Car-T, Nk, Γδ T, Stem Cell, T-Reg)

Bruce Ng

Gene/Cell Therapy Cmc Program Management

Hong Ma

Senior Md In Cancer Immunotherapy & Autoimmune Diseases

Xu (Dawn) Guo

Bd Head

Free Chrome Extension

Aero Online

Select data to include:

How It Works

Get a Free Account

Search the #1 Contact Database

Use our AI-Powered Email Finder

Have a look at Aeroleads Data